Butyric Acid

Butyric Acid

SCHEMBL1017693

CCCC(=O)O.N.N.O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Butyric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butyric Acid SCHEMBL1596394 0.97 FFAR3 (0.81)
Butyric Acid SCHEMBL5642475 0.97 FFAR3 (0.81)
Butyric Acid SCHEMBL1650329 0.97
Butyric Acid SCHEMBL7879075 0.97 FFAR3 (0.93)
Butyric Acid SCHEMBL28476290 0.97 FFAR3 (0.93)
Butyric Acid SCHEMBL358880 0.97
Butyric Acid SCHEMBL2230669 0.97 FFAR3 (0.93)
Butyric Acid SCHEMBL2234517 0.97
Butyric Acid SCHEMBL10520334 0.97 FFAR3 (0.93)
Butyric Acid SCHEMBL28462096 0.97 FFAR3 (0.93)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108037192-A A kind of Liquid Chromatography-Tandem Mass Spectrometry that can detect five class medicines in edible animal product and feed at the same time 华中农业大学 2018-05-15 CN claimed
CN-109331029-A Tannic acid shorten the growing and fattening pigs off-drug period in application, composition and composition application 长沙绿叶生物科技有限公司 2019-02-15 CN disclosed
CN-108037192-A A kind of Liquid Chromatography-Tandem Mass Spectrometry that can detect five class medicines in edible animal product and feed at the same time 华中农业大学 2018-05-15 CN disclosed
EP-3089986-A1 CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE Rxbio Inc. (US) 2016-11-09 EP disclosed
US-20150342935-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL MYERS SQUIBB CO (US) 2015-12-03 US disclosed
CN-102791718-B Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB CO. (US) 2015-11-25 CN disclosed
WO-2015102856-A1 CRYSTALLINE SALTS OF (Z)-O-OCTADEC-9-EN-1-YL O,O-DIHYDROGEN PHOSPHOROTHIOATE RXBIO INC. (US) 2015-07-09 WO disclosed
CN-103025744-A Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs BRISTOL MYERS SQUIBB CO 2013-04-03 CN disclosed
EP-2563796-A1 AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS Bristol-Myers Squibb Company (US) 2013-03-06 EP disclosed
EP-2493892-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS Bristol-Myers Squibb Company (US) 2012-09-05 EP disclosed
US-6440989-B2 ANTITUMOR AGENT SCHERING CORPORATION 2002-08-27 US disclosed
US-20010016585-A1 Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase AFONSO ADRIANO (IN) 2001-08-23 US disclosed
US-6218401-B1 FOR THERAPY OF PANCREATIC TUMOR CELLS, LUNG CANCER CELLS, MYELOID LEUKEMIA TUMOR CELLS, THYROID FOLLICULAR TUMOR CELLS, MYELODYSPLASTIC TUMOR CELLS, EPIDERMAL CARCINOMA TUMOR CELLS, BLADDER CARCINOMA TUMOR CELLS OR PROSTATE TUMOR CELLS SCHERING CORPORATION 2001-04-17 US disclosed
EP-0478954-B1 Serotonin 5HT1A and 5HT1D agonists MERRELL PHARMA INC (US) 2000-10-18 EP disclosed
EP-0989981-A1 NOVEL PHENYL-SUBSTITUTED TRICYCLIC INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2000-04-05 EP disclosed
WO-1998057950-A1 NOVEL PHENYL-SUBSTITUTED TRICYCLIC INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE SCHERING CORPORATION (US) 1998-12-23 WO disclosed
US-5559143-A Serotonin 5HT1A agonistic method MERRELL PHARMACEUTICALS INC. (US) 1996-09-24 US disclosed
US-5387604-A 1,4 benzodioxin derivatives and their use as serotonin 5HT1A agonists MERRELL DOW PHARMACEUTICALS INC. (US) 1995-02-07 US disclosed
US-5189179-A SEROTONIN 5HT1A AGONISTS MERRELL DOW PHARMACEUTICALS INC. (US) 1993-02-23 US disclosed
EP-0478954-A1 Serotonin 5HT1A and 5HT1D antagonists MERRELL PHARMACEUTICALS INC. (US) 1992-04-08 EP disclosed